Compare IDEXX Laboratories, Inc. (IDXX) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Tyson Foods, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Tyson Foods, Inc. trades at $53.43 (market cap $18.41B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.2× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays a 3.9% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Tyson Foods, Inc. for 76 Days on average.
| IDXX | TSN | |
|---|---|---|
Market Cap | $40.43B | $18.41B |
Volume | 692,164 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $68.75 |
52-Week Low | $504.70 | $50.47 |
Typical Hold Time | 46 Days | 76 Days |
Enterprise Value | $41.32B | $25.68B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Tyson Foods (TSN) trades at $52.34, up 1.24% on the day, with a bullish technical signal but mixed earnings history including a recent Q4 2025 miss. Valuation ratios like P/S of 0.33 appear attractive, but thin net margins of 1.03% and ongoing cash flow challenges highlight operational pressures. Recent news includes a lowered fiscal 2026 outlook and a securities investigation, adding uncertainty despite insider buying and institutional interest.
The stock offers a potential 25% upside to the consensus price target of $65.40, supported by a majority analyst buy rating. However, risks are elevated from beef segment losses, negative cash flows, and legal scrutiny. Investor sentiment is cautious amid guidance cuts, making earnings execution critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
